Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.
Survival in newly diagnosed multiple myeloma improved significantly in patients who underwent early autologous stem cell transplantation (ASCT), according to pooled data from two randomized trials.
The 4-year overall survival was 85% in patients who underwent stem cell transplantation as consolidation therapy versus 76% for those who had transplants after first relapse, reported Federica Cavallo, MD, PhD, of the University of Torino in Italy, and colleagues.
Median time to first progression (PFS1) was almost twice as long in patients who had early stem cell transplantation, and the time to second relapse also was significantly delayed by early transplantation, they said at the European Hematology Association meeting.
Read the original report here: http://bit.ly/V5ycMW
Source: Medpage Today
Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, discussed how the transition to value-based care can contribute to operational and financial risks among oncology practices, and the effectiveness of care navigation platforms in addressing these concerns.
Read More
Osimertinib Demonstrates Overall Survival Benefit as Adjuvant Lung Cancer Treatment
March 19th 2023Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Even Oncologists Sold on Value-Based Care Hesitate to Embrace the EOM
March 10th 2023Members of the Association of Community Cancer Centers (ACCC) Alternative Payment Coalition discussed strategies for succeeding in value-based care and voiced concerns surrounding the upcoming Enhancing Oncology Model (EOM) during a panel discussion at the ACCC 2023 Annual Meeting and Business Summit.
Read More
Stops and Starts Abound in the Oncology Payment Landscape
March 10th 2023A session at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and payment, from the Cures 2.0 Act to 340B drug reimbursement.
Read More
2 Clarke Drive
Cranbury, NJ 08512